Compare Definium Therapeutics Inc. Common Shares (DFTX) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.4 (market cap $4.59B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.22 (market cap $2.27B). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 2× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is more actively traded (4,179,659 versus 2,103,937). Which is the better fit depends on your goals.
| DFTX | SLS | |
|---|---|---|
Market Cap | $4.59B | $2.27B |
Volume | 2,103,937 | 4,179,659 |
Sector | Health | Health |
52-Week High | $48.45 | $15.46 |
52-Week Low | $10.68 | $1.39 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $3.55B | $2.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
